Advertisement

Loading...

Theratechnologies Inc.

TH.TOTSX
Healthcare
Drug Manufacturers - Specialty & Generic
$4.47
$-0.23(-4.89%)
Canadian Market opens in 15h 3m

Theratechnologies Inc. Fundamental Analysis

Theratechnologies Inc. (TH.TO) shows moderate financial fundamentals with a PE ratio of -12.97, profit margin of -19.83%, and ROE of 47.31%. The company generates $0.1B in annual revenue with moderate year-over-year growth of 5.02%.

Key Strengths

ROE47.31%
PEG Ratio0.11

Areas of Concern

Operating Margin1.47%
Cash Position4.50%
Current Ratio0.84
We analyze TH.TO's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 49.8/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

D
49.8/100

We analyze TH.TO's fundamental strength across five key dimensions:

Efficiency Score

Weak

TH.TO struggles to generate sufficient returns from assets.

ROA > 10%
-23.89%

Valuation Score

Excellent

TH.TO trades at attractive valuation levels.

PE < 25
-12.97
PEG Ratio < 2
0.11

Growth Score

Excellent

TH.TO delivers strong and consistent growth momentum.

Revenue Growth > 5%
5.02%
EPS Growth > 10%
48.48%

Financial Health Score

Moderate

TH.TO shows balanced financial health with some risks.

Debt/Equity < 1
-1.56
Current Ratio > 1
0.84

Profitability Score

Weak

TH.TO struggles to sustain strong margins.

ROE > 15%
47.31%
Net Margin ≥ 15%
-19.83%
Positive Free Cash Flow
No

Key Financial Metrics

Is TH.TO Expensive or Cheap?

P/E Ratio

TH.TO trades at -12.97 times earnings. This suggests potential undervaluation.

-12.97

PEG Ratio

When adjusting for growth, TH.TO's PEG of 0.11 indicates potential undervaluation.

0.11

Price to Book

The market values Theratechnologies Inc. at -5.69 times its book value. This may indicate undervaluation.

-5.69

EV/EBITDA

Enterprise value stands at -24.91 times EBITDA. This is generally considered low.

-24.91

How Well Does TH.TO Make Money?

Net Profit Margin

For every $100 in sales, Theratechnologies Inc. keeps $-19.83 as profit after all expenses.

-19.83%

Operating Margin

Core operations generate 1.47 in profit for every $100 in revenue, before interest and taxes.

1.47%

ROE

Management delivers $47.31 in profit for every $100 of shareholder equity.

47.31%

ROA

Theratechnologies Inc. generates $-23.89 in profit for every $100 in assets, demonstrating efficient asset deployment.

-23.89%

Following the Money - Real Cash Generation

Operating Cash Flow

Theratechnologies Inc. generates limited operating cash flow of $2.27M, signaling weaker underlying cash strength.

$2.27M

Free Cash Flow

Theratechnologies Inc. generates weak or negative free cash flow of $-7.15M, restricting financial flexibility.

$-7.15M

FCF Per Share

Each share generates $-0.16 in free cash annually.

$-0.16

FCF Yield

TH.TO converts -5.19% of its market value into free cash.

-5.19%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-12.97

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.11

vs 25 benchmark

P/B Ratio

Price to book value ratio

-5.69

vs 25 benchmark

P/S Ratio

Price to sales ratio

2.40

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-1.56

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.84

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.47

vs 25 benchmark

ROA

Return on assets percentage

-0.24

vs 25 benchmark

ROCE

Return on capital employed

0.08

vs 25 benchmark

How TH.TO Stacks Against Its Sector Peers

MetricTH.TO ValueSector AveragePerformance
P/E Ratio-12.9728.31 Better (Cheaper)
ROE47.31%699.00% Weak
Net Margin-19.83%-131318.00% (disorted) Weak
Debt/Equity-1.560.34 Strong (Low Leverage)
Current Ratio0.842775.16 Weak Liquidity
ROA-23.89%-14513.00% (disorted) Weak

TH.TO outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Theratechnologies Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

111.68%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

-3.59%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

209.34%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ